Lawrence’s NxStage Medical Inc. jumped after the dialysis products manufacturer’s preliminary fourth-quarter sales numbers beat its own and analysts’ expectations. NxStage said it expects revenue of about $69 million, above its earlier guidance of between $67 and $68.5 million. The Street estimated $67.8 million. “. . . we continue to target 15 percent annual revenue growth in the home in 2014,” CEO Jeffrey Burbank said in a statement. For the full-year 2013, NxStage expects revenue of $263 million, above estimates. Full story for BostonGlobe.com subscribers.
This is a summary. To read the whole story subscribe to BostonGlobe.com
© Copyright 2014 Globe Newspaper Company.
Get the full story with unlimited access to BostonGlobe.com. Just 99¢ for 4 weeks.